免疫疗法时代的空间分割放射治疗

IF 2.6 3区 医学 Q3 ONCOLOGY
Matthew T. McMillan , Atif J. Khan , Simon N. Powell , John Humm , Joseph O. Deasy , Adriana Haimovitz-Friedman
{"title":"免疫疗法时代的空间分割放射治疗","authors":"Matthew T. McMillan ,&nbsp;Atif J. Khan ,&nbsp;Simon N. Powell ,&nbsp;John Humm ,&nbsp;Joseph O. Deasy ,&nbsp;Adriana Haimovitz-Friedman","doi":"10.1016/j.semradonc.2024.04.002","DOIUrl":null,"url":null,"abstract":"<div><p>Spatially fractionated radiotherapy (SFRT) includes historical grid therapy approaches but more recently encompasses the controlled introduction of one or more cold dose regions using intensity modulation delivery techniques. The driving hypothesis behind SFRT is that it may allow for an increased immune response that is otherwise suppressed by radiation effects. With both two- and three-dimensional SFRT approaches, SFRT dose distributions typically include multiple dose cold spots or valleys. Despite its unconventional methods, reported clinical experience shows that SFRT can sometimes induce marked tumor regressions, even in patients with large hypoxic tumors. Preclinical models using extreme dose distributions (i.e., half-sparing) have been shown to nevertheless result in full tumor eradications, a more robust immune response, and systemic anti-tumor immunity. SFRT takes advantage of the complementary immunomodulatory features of low- and high-dose radiotherapy to integrate the delivery of both into a single target. Clinical trials using three-dimensional SFRT (i.e., lattice-like dose distributions) have reported both promising tumor and toxicity results, and ongoing clinical trials are investigating synergy between SFRT and immunotherapies.</p></div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":"34 3","pages":"Pages 276-283"},"PeriodicalIF":2.6000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Spatially Fractionated Radiotherapy in the Era of Immunotherapy\",\"authors\":\"Matthew T. McMillan ,&nbsp;Atif J. Khan ,&nbsp;Simon N. Powell ,&nbsp;John Humm ,&nbsp;Joseph O. Deasy ,&nbsp;Adriana Haimovitz-Friedman\",\"doi\":\"10.1016/j.semradonc.2024.04.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Spatially fractionated radiotherapy (SFRT) includes historical grid therapy approaches but more recently encompasses the controlled introduction of one or more cold dose regions using intensity modulation delivery techniques. The driving hypothesis behind SFRT is that it may allow for an increased immune response that is otherwise suppressed by radiation effects. With both two- and three-dimensional SFRT approaches, SFRT dose distributions typically include multiple dose cold spots or valleys. Despite its unconventional methods, reported clinical experience shows that SFRT can sometimes induce marked tumor regressions, even in patients with large hypoxic tumors. Preclinical models using extreme dose distributions (i.e., half-sparing) have been shown to nevertheless result in full tumor eradications, a more robust immune response, and systemic anti-tumor immunity. SFRT takes advantage of the complementary immunomodulatory features of low- and high-dose radiotherapy to integrate the delivery of both into a single target. Clinical trials using three-dimensional SFRT (i.e., lattice-like dose distributions) have reported both promising tumor and toxicity results, and ongoing clinical trials are investigating synergy between SFRT and immunotherapies.</p></div>\",\"PeriodicalId\":49542,\"journal\":{\"name\":\"Seminars in Radiation Oncology\",\"volume\":\"34 3\",\"pages\":\"Pages 276-283\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2024-06-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in Radiation Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1053429624000225\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1053429624000225","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

空间分割放射治疗(SFRT)包括历史上的网格治疗方法,但最近又包括利用强度调制传输技术有控制地引入一个或多个冷剂量区。空间分割放疗背后的驱动假设是,它可以增加免疫反应,否则放射效应会抑制免疫反应。在二维和三维 SFRT 方法中,SFRT 剂量分布通常包括多个剂量冷斑或冷谷。尽管采用的是非常规方法,但据报道的临床经验表明,SFRT 有时可诱导肿瘤明显消退,即使是患有大面积缺氧性肿瘤的患者也不例外。使用极端剂量分布(即半保留)的临床前模型已被证明可以完全根除肿瘤,产生更强大的免疫反应和全身抗肿瘤免疫力。SFRT利用了低剂量和高剂量放疗的互补免疫调节特性,将两者的放疗整合到一个靶点上。使用三维 SFRT(即格子状剂量分布)进行的临床试验报告了良好的肿瘤和毒性效果,目前正在进行的临床试验正在研究 SFRT 与免疫疗法之间的协同作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Spatially Fractionated Radiotherapy in the Era of Immunotherapy

Spatially fractionated radiotherapy (SFRT) includes historical grid therapy approaches but more recently encompasses the controlled introduction of one or more cold dose regions using intensity modulation delivery techniques. The driving hypothesis behind SFRT is that it may allow for an increased immune response that is otherwise suppressed by radiation effects. With both two- and three-dimensional SFRT approaches, SFRT dose distributions typically include multiple dose cold spots or valleys. Despite its unconventional methods, reported clinical experience shows that SFRT can sometimes induce marked tumor regressions, even in patients with large hypoxic tumors. Preclinical models using extreme dose distributions (i.e., half-sparing) have been shown to nevertheless result in full tumor eradications, a more robust immune response, and systemic anti-tumor immunity. SFRT takes advantage of the complementary immunomodulatory features of low- and high-dose radiotherapy to integrate the delivery of both into a single target. Clinical trials using three-dimensional SFRT (i.e., lattice-like dose distributions) have reported both promising tumor and toxicity results, and ongoing clinical trials are investigating synergy between SFRT and immunotherapies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
5.80
自引率
0.00%
发文量
48
审稿时长
>12 weeks
期刊介绍: Each issue of Seminars in Radiation Oncology is compiled by a guest editor to address a specific topic in the specialty, presenting definitive information on areas of rapid change and development. A significant number of articles report new scientific information. Topics covered include tumor biology, diagnosis, medical and surgical management of the patient, and new technologies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信